Please assess the completion status of the following clinical trial:

Trial Title: A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Dispensation or any other record of empagliflozin, any SGLT-2 inhibitor, or any DPP-4 inhibitor use during the study period~* No dispensation or any other record of any other SGLT-2 inhibitor or DPP-4 inhibitor use during the preceding 12 months including at index date~* Having a diagnosis of T2DM before the index date, based on ICD-10 codes or other available data~Exclusion Criteria:~* Aged \<18 years on the first dispensation date or date of the first record of empagliflozin, any SGLT-2 inhibitor or any DPP-4 inhibitor use~* Type 1 diabetes mellitus~* Secondary diabetes~* Gestational diabetes~* Having a diagnosis of ESRD during the 12 months before the index date~* \<12 months of available data before the index date, and/or no complete history of drug dispensations/other records of the drug use during this period~* Missing or ambiguous data on age or sex

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- New users of SGLT-2i (Type: None): Patients with type 2 diabetes mellitus (T2DM), who were new users of any sodium-glucose cotransporter-2 inhibitors (SGLT-2i) including empagliflozin.
- New users of DPP-4i (Type: None): Patients with type 2 diabetes mellitus (T2DM), who were new users of dipeptidyl peptidase-4 inhibitors (DPP-4i).

Based on this trial design, predict the completion outcome and termination type (if applicable).